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Abstract: Cancer-associated cachexia (CAC) is the nutrition-independent loss of lean muscle and
adipose tissues, and results in reduced chemotherapy effectiveness and increased mortality. Preventing adipose loss is considered a key target in the early stages of cachexia. Lipolysis is considered
the central driver of adipose loss in CAC. We recently found that piceatannol, but not its analogue
resveratrol, exhibits an inhibitory effect on lipolysis. The objective of this study was to investigate
the role of piceatannol in cancer-associated lipolysis and cachexia-induced weight loss. Cancer cellinduced lipolysis in adipocytes was stimulated using cancer-conditioned media (CCM) or co-culture
with human pancreatic cancer cells and the cachexia-associated cytokines TNF-α and interleukin-6 in
3T3-L1 adipocytes. C26 colon carcinoma-bearing mice were modeled using CAC in vivo. Piceatannol
reduced cancer-associated lipolysis by at least 50% in both CCM and cytokine-induced lipolysis
in vitro. Further gene and protein analysis confirmed that piceatannol modulated the stability of
lipolytic proteins. Moreover, piceatannol protected tumor-bearing mice against weight-loss in early
stages of CAC largely through preserving adipose tissue, with no effect on survival. This study
demonstrates the use of a dietary compound to preserve adipose in models of early stage CAC and
provides groundwork for further investigation of piceatannol or piceatannol-rich foods as alternative
medicine in the preservation of body fat mass and future CAC therapy.
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1. Introduction
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The uncontrolled wasting induced by cancer-associated cachexia (CAC) results in
functional impairment, decreased chemotherapy effectiveness, lower quality of life, and
poorer survival outcomes [1,2]. CAC is the direct cause of death in up to 20% of all cancer
mortalities [1,3]. CAC is characterized by an ongoing loss of adipose and lean muscle,
which cannot be overcome with nutritional interventions [4,5]. Although the causes of CAC
are not fully understood, dysregulated energy balance likely plays a significant role [6–8].
Despite the lack of a universal treatment strategy, managing symptoms of CAC can increase
survival and improve quality of life [9,10].
While CAC treatments have historically focused on minimizing lean muscle loss,
recent studies indicate an increasingly important role of adipose atrophy. Of note, adipose
loss precedes muscle loss and inversely correlates with survival in cancer patients [6,11–13].
Preventing white adipose tissue (WAT) depletion is considered an important strategy in
overall body weight preservation in CAC [6]. Lipolysis, the hydrolysis of stored triglycerides (TG), is primarily responsible for adipose loss in CAC rather than factors such as
impaired lipogenesis or adipogenesis [14–16]. Furthermore, targeting the principle and
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rate-limiting lipolytic enzyme, adipose triglyceride lipase (ATGL), preserves both muscle
and adipose tissue in mice [17]. Of note, ATGL accounts for up to 70–85% of adipocyte
lipolysis [18,19]. Interestingly, pharmacological inhibition of ATGL reduced weight gain
and insulin resistance in mouse models of obesity [20], thus providing evidence that lipolysis inhibition is unlikely to result in weight gain. Cancer-induced changes in circulating
factors, such as IL-6 and tumor necrosis factor-α (TNF-α), contribute to increased adipose
lipolysis in CAC, possibly through modulating ATGL [15,17,21,22]. Due to the established
role of cancer-secreted factors in CAC, cancer conditioned media (CCM) has been used for
mechanistic studies of the syndrome [6,8,23–25].
Piceatannol, a naturally occurring resveratrol analogue, is found in a variety of
food sources and has numerous reported health benefits, including anti-cancer, antiinflammatory, and anti-adipogenic properties [26–28]. Additionally, we and others recently
found that piceatannol inhibited lipolysis in vitro and in vivo [29,30]. Unlike resveratrol, we
found that piceatannol induced degradation of lipolytic proteins in adipocytes, including
ATGL, its co-activator comparative gene identification-58 (CGI-58), and perilipin1 (PLIN1),
in an autophagy-dependent manner. However, whether piceatannol’s anti-lipolytic properties influence CAC-associated lipolysis is unknown.
The aim of this study was to investigate the protective role of piceatannol in models of
CAC. Because piceatannol reduces lipolysis via degradation of the ATGL-CGI-58-perilipin
lipolytic protein cluster in adipocytes and ATGL plays an important role in CAC adipose
loss, we postulated that it would prevent CAC-induced lipolysis in vitro and weight
loss in vivo. CAC-associated lipolysis was stimulated by exposing 3T3-L1 adipocytes to
(1) established human pancreatic cancer cell lines, a cancer type highly associated with
CAC, using CCM and co-culture (PANC-1 and AsPC-1, respectively); and (2) lipolytic
CAC-associated cytokines TNF-α and IL-6 [1]. We demonstrated that piceatannol blocked
CAC-associated lipolysis in all in vitro models tested. Furthermore, piceatannol slowed
tumor-induced weight-loss and adipose atrophy in colon-26 (C26) carcinoma-bearing
mice. We provide novel evidence that a dietary compound, piceatannol, may possess
anti-CAC properties.
2. Materials and Methods
2.1. Cell Culture
Murine 3T3-L1 preadipocytes were purchased from American Type Culture Collection
(Manassas, VA, USA). Briefly, pre-adipocytes were maintained in DMEM supplemented
with 10% fetal calf serum (FCS), 1% sodium pyruvate, and 1% penicillin-streptomycin.
Cells were passaged prior to reaching 80% confluence. To differentiate, preadipocytes
were grown to confluence; two days post-confluence (designated as day 0), preadipocytes
were treated with differentiation media consisting of 10% fetal bovine serum (FBS), 0.5 mM
3-Isobutyl-1-methylxanthine (IBMX), 1 µM dexamethasone, and 167 nM or 334 nM insulin. On day 2, media was removed and replaced by 10% FBS with 167 nM or 334 nM
insulin, with or without 2 µM rosiglitazone to maximize lipid droplet growth. On day 4,
differentiation media was replaced with standard media, with or without insulin, and
maintained until maturity. PANC-1 human pancreatic carcinoma cells and NIH-3T3 fibroblast cells were maintained in DMEM supplemented with 10% FBS and 10% FCS,
respectively, and passaged prior to reaching confluence. Mature adipocytes were used
for all experiments. Unless otherwise noted, serum-free media (SFM) refers to DMEM
supplemented with 1% BSA, 1% sodium pyruvate, and 1% penicillin-streptomycin. Conditioned media was obtained by culturing confluent PANC-1 cells (CCM) or NIH-3T3
cells (fibroblast-conditioned media, FCM, control condition) overnight in SFM. Media was
collected, centrifuged at 4750× g for 5 min, aliquoted, and stored at –20 ◦ C until use. For
co-culture experiments, AsPC-1 human pancreatic cancer cells were grown on 6-well plate
transwell inserts (Corning, Lowell, MA, USA), then co-cultured with either HPDE6 human
pancreatic duct epithelial cells or 3T3-L1 cells for the indicated time.
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2.2. In Vitro Model of CAC-Induced Lipolysis
To simulate CAC-induced lipolysis, adipocytes were first pre-treated with the stimulus
(e.g., TNF-α, IL-6, or CCM) for 16 h, based on the observation of TNF-α’s maximum effect
on lipolysis [31]. Adipocytes were then co-treated with stimulus and piceatannol (Enzo
Life Sciences, Farmingdale, NY, USA) for 8 h, based on optimal piceatannol stability (data
not shown). Commercial kits were used to measure glycerol release (Sigma, St. Louis,
MO, USA) and free fatty acids (Cayman Chemical, Ann Arbor, MI, USA), as indicators
of lipolysis.
2.3. Western Blot
Cells were collected by scraping in ice-cold phosphate buffered saline (PBS). After a
light centrifugation, the PBS supernatant was removed and lysis buffer (100 mM Tris-HCl,
pH 8.0, 100 mM NaCl, 0.5% NP-40) with protease inhibitors was mixed with the cell pellet
and allowed to sit on ice for 10 min. After centrifugation, the supernatant was collected, and
protein concentration was measured using the Bradford method. Protein was loaded onto
SDS-PAGE gels and separated by electrophoresis. Proteins were then transferred to either
a nitrocellulose or polyvinylidene fluoride membrane and incubated with the antibody
of interest. Antibodies against β-actin and rabbit secondary antibody were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA). Antibody against comparative gene
identification-58 (CGI-58) was obtained from Biovision Inc. (Milpitas, CA, USA). Mouse
secondary antibody was obtained from Jackson ImmunoResearch Laboratories, Inc. (West
Grove, PA, USA). Antibodies against adipose triglyceride lipase (ATGL), and phosphohormone sensitive lipase (HSL) was obtained from Cell Signaling Technology (Danvers,
MA, USA). STAT3 and phospho-STAT3 antibodies were obtained from R&D Systems
(Minneapolis, MN, USA). Ponceau S staining was used to confirm transfer efficiency. The
membrane was then incubated with the corresponding horseradish peroxidase-linked
secondary antibody. Proteins were visualized using enhanced chemiluminescence reagents.
2.4. Isolation of Total RNA and PCR
Total RNA was extracted using TRIzol reagent, according to the manufacturer’s
protocol. Isolated RNA (2 µg/µL) in combination with M-MuLV reverse transcriptase kit
was used to synthesize cDNA, then amplified by PCR. Quantitative PCR was performed
using diluted cDNA, primers of interest, and SYBR green Taq mixture in the StepOne realtime PCR system (Applied Biosystems, Foster City, CA, USA). The primer sequences are as
follows: β-actin (forward, 50 -AGA TGA CCC AGA TCA TGT TTG AGA-30 ; reverse, 50 -CAC
AGC CTG GAT GGC TAC GT-30 ); ATGL (forward, 50 -GAG ACC AAG TGG AAC ATC-30 ;
reverse, 50 -GTA GAT GTG AGT GGC GTT-30 ); Perilipin (forward, 50 -TGC TGG ATG GAG
ACC TC-30 ; reverse, 50 -ACC GGC TCC ATG CTC CA-30 ); CGI-58 (forward, 50 -GGT TAA
GTC TAG TGC AGC-30 ; reverse, 50 -AAG CTG TCT CAC CAC-30 ); HSL (forward, 50 -ACT
CAG ACC AGA AGG CAC TA-30 ; reverse, 50 -TAG TTC CAG GAA GGA GTT GA-30 ).
2.5. Cell Viability
Thiazolyl blue tetrazolium bromide (MTT) was dissolved in PBS at a concentration
of 5 mg/mL and filtered. MTT solution was added to fresh SFM at a concentration of
100 µL/mL and cultured for one hour at 37 ◦ C with 3T3-L1 cells in a 24-well plate following
experimental treatment. The medium was aspirated and resulting formazan crystals were
dissolved in 300 µL of DMSO. Following an additional 1:1 dilution with DMSO, the solution
from each well was measured spectrophotometrically at 595 nm using a microplate reader.
2.6. Animal Experiment
Mice studies were approved by the Purdue Animal Care and Use Committee (protocol
no.: 112000342). Male BALBc mice (7 weeks old) (Jackson Laboratories, Bar Harbor, ME,
USA) were fed a standard 18% protein chow diet. After a 2-week adjustment period, mice
were randomly divided into three groups: non-tumor bearing (NT, n = 4), tumor-bearing
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(TB, n = 9), and piceatannol-treated tumor bearing (PTB, n = 9). Mice received an injection
of either PBS in the NT group or 5 × 105 murine C26 colorectal carcinoma cells in the
TB and PTB groups in the inguinal brown adipose tissue (day 0), an established model
of CAC [32]. Piceatannol (4 mg/mL) was dissolved in 30% PEG-400, 1% polysorbate-80,
and 1% ethanol to create a treatment stock solution. Stock solutions were stored at 4 ◦ C
and prepared fresh twice per week. After tumors became palpable (day 5), tumor-bearing
mice received daily intraperitoneal (i.p.) injections of either piceatannol (20 mg/kg BW) or
vehicle alone. This dose of piceatannol was chosen based on our previous observations
that i.p. administration of piceatannol higher than 10 mg/kg BW was needed to exhibit
significant reduction of lipolysis in lean mice [30]. Tumor volume was measured using
calipers. Body score was determined by a trained technician, where 3 indicated a mouse
in optimal condition, 2 indicated under-conditioning and prominent appearance of the
skeletal structure, and 1 indicated advanced muscle and fat wasting and very prominent
appearance of the skeletal structure [33]. Individual mice were euthanized when weight
loss exceeded 20% of initial body weight. To determine the effect of piceatannol on survival,
mice continued to receive treatment until euthanasia criteria was met. Prior to euthanasia,
body composition was determined using Echo-MRI (Echo Medical Systems, Houston, TX,
USA). Mice were then euthanized via asphyxiation and cervical dislocation. Data shown
are from day 12, when the first mouse met euthanasia criteria.
2.7. Statistical Analysis
Statistical analysis was conducted using Minitab 17 (Minitab Inc., State College,
PA, USA). Student’s t-test or one-way ANOVA followed by Tukey’s post-hoc difference
test were used to determine statistical difference at p < 0.05. Data shown represent the
mean ± standard error of the mean (SEM). Data with different letters are considered statistically different. Survival analysis was conducted using Kaplan–Meier estimates (OriginLab
Corp., Northampton, MA, USA).
3. Results
3.1. Piceatannol Blocks Cancer-Associated Lipolysis In Vitro
As lipolysis is the main driver of adipose loss in CAC and we previously revealed
an anti-lipolytic effect of piceatannol [30], herein we investigated the role of piceatannol
in cancer-associated lipolysis. To examine the cancer-associated lipolysis in vitro, we
first confirmed the lipolytic effect of CAC-associated stimuli. The CAC-associated proinflammatory cytokines, TNF-α (Figure 1A) and IL-6 (Figure 1B) and CCM from PANC-1
human pancreatic cancer cells (Figure 1C) promoted lipolysis in mature 3T3-L1 adipocytes
as judged by an increase in glycerol release and free fatty acids (FFA). Furthermore, we
confirmed that the effects of piceatannol and CAC stimulators were not due to decreased
cell viability (Figure 2A). In both cytokine-induced and PANC-1-derived CCM-induced
lipolysis, an 8-h 50 µM piceatannol treatment reduced glycerol and FFA release by at least
50% (Figure 2B,C). Furthermore, piceatannol also inhibited lipolysis induced by three hours
in transwell co-culture of 3T3-L1 adipocytes with AsPC-1 human pancreatic cells (CANC)
relative to co-culture with non-transformed HPDE6 (CONT) control cells (Figure 2D).
Observations of piceatannol’s inhibitory role in multiple models of cancer-associated
lipolysis suggest a role of this phytochemical in CAC lipolysis.
3.2. Piceatannol Induces Post-Transcriptional Degradation of ATGL and CGI-58
Our recent study demonstrated that piceatannol induced degradation of ATGL and its
co-activator CGI-58 in an autophagy-dependent manner [30]. Therefore, our next objective
was to verify whether a similar mechanism mediated piceatannol action in models of CAC.
In support of piceatannol’s post-transcriptional regulation of lipolytic machinery, we found
no difference in mRNA expression of ATGL, CGI-58, HSL, and perilipin in TNF-α, IL-6, and
CCM-treated adipocytes (Figure 3A,B). Consistent with our previous findings, piceatannol
induced ATGL and CGI-58 degradation in both TNF-α and CCM stimulated conditions
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(Figure 3C,D). On the other hand, we found that piceatannol increased the pro-lipolytic
serine 660 phosphorylation of HSL, a key event in HSL activation [34] (Figure 3C). As the
inflammatory cytokine IL-6 mediates adipose loss in various in vivo models of CAC [35],
and piceatannol is suggested to inhibit IL-6 signaling and secretion and its associated
signal-transducer-and-activator-of-transcription 3 (STAT3) signaling pathway [36,37], we
determined the effect of piceatannol on CAC-induced STAT3 activity in adipocytes. We
observed that piceatannol suppressed STAT3 phosphorylation in CCM-treated adipocytes,
of 14Taken
although the difference was not statistically significant (p = 0.100) (Figure 53E).
together, our results support the hypothesis that piceatannol inhibits lipolysis via posttranscriptional modification of ATGL and CGI-58.
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Figure 2. Piceatannol prevents cancer-associated lipolysis. (A) Mature 3T3-L1 adipocytes treated
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less fat mass than NT mice, while piceatannol treatment preserved body fat mass in PTB
mice (Figure 4B). A significant difference in percent fat mass, but not percent lean mass in
TB mice (Figure 4C) suggests that piceatannol protected body weight primarily through
preservation of adipose tissue. No difference was detected in food intake (Figure 4D) and
Nutrients 2022, 14,
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REVIEW
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Figure
3. Alterations
in expression
of lipolytic
proteins
and genes and
by piceatannol
and cancer-associated stimuli. Mature 3T3-L1 adipocytes were pre-treated with lipolytic stimuli for 16 h followed
by 8 h stimuli-piceatannol (50 mM) co-treatment (A,B,D,E) or 16 h stimuli-piceatannol co-treatment
only (C). These cells were subjected to total RNA isolation to determine the mRNA levels of genes
involved in lipolysis (adipose triglyceride lipase (ATGL), comparative gene identification-58 (CGI58), hormone-sensitive lipase (HSL), and Perilipin) (A,B). Signals were normalized to β-actin (n = 3).
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stimuli. Mature 3T3-L1 adipocytes were pre-treated with lipolytic stimuli for 16 h followed by 8 h
stimuli-piceatannol (50 mM) co-treatment (A,B,D,E) or 16 h stimuli-piceatannol co-treatment only (C).
These cells were subjected to total RNA isolation to determine the mRNA levels of genes involved in
lipolysis (adipose triglyceride lipase (ATGL), comparative gene identification-58 (CGI-58), hormonesensitive lipase (HSL), and Perilipin) (A,B). Signals were normalized to β-actin (n = 3). The expression
levels of ATGL, CGI-58, pHSLser660 , phosphorylated signal-transducer-and-activator-of-transcription
3 (pSTAT3), and STAT3 in these cells were determined by Western blot analysis using β-actin as a
loading control (C,D,E). Values represent relative density of pSTAT3/total STAT3 from three blots.
Nutrients 2022, 14, x FOR PEER REVIEW
9 of 14
Treatments with different letters are statistically different, as determined by ANOVA followed by
Tukey’s post-hoc analysis (p < 0.05). All data presented were mean ± S.E.M.

Figure 4. Piceatannol
Piceatannol affects body
body weight
weight independent
independent of
of tumor
tumor growth
growth and
and food
food intake.
intake. Non-tuNon-tumor
mor bearing (NT, n = 4) or C26 colorectal carcinoma tumor-bearing (TB, n = 9) male BALBc received
a vehicle or piceatannol (PTB, n = 9) beginning on day 5. (A) Body-weight, (B) fat mass, (C) lean
mass, (D) average daily food intake, (E) tumor volume (F), and body score (G) are shown. (G) The
Kaplan–Meier estimator of survival of the mice in TB and PTB. All data presented were mean ±
S.E.M. p values were calculated using Student’s t-test. *, p < 0.05.
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bearing (NT, n = 4) or C26 colorectal carcinoma tumor-bearing (TB, n = 9) male BALBc received
a vehicle or piceatannol (PTB, n = 9) beginning on day 5. (A) Body-weight, (B) fat mass, (C) lean
mass, (D) average daily food intake, (E) tumor volume (F), and body score (G) are shown. (G) The
Kaplan–Meier estimator of survival of the mice in TB and PTB. All data presented were mean ± S.E.M.
p values were calculated using Student’s t-test. *, p < 0.05.

4. Discussion
In this study, we revealed a novel role of a dietary compound, piceatannol, in blunting
cancer-associated lipolysis in vitro, and adipose and body-weight loss in a mouse model
of cachexia. Despite increasing interest in natural anti-cancer compounds, little is known
about dietary modulation of cancer-associated adipose wasting. Although others have
demonstrated a role of naturally occurring bioactive compounds, such as alantolactone [40],
nicotinamide [41], coix seed oil [42], and carnosol [43], in slightly alleviating fat loss, our
study is the first report, to our knowledge, of a dietary compound exhibiting protection of
adipose tissue in early stages of CAC. These results add needed evidence to support the
protective role of dietary compounds generally and piceatannol specifically in preserving
adipose tissue and lowering lipolysis in models of CAC.
Adipose lipolysis in general, and ATGL specifically, are considered key targets to
preserve body weight in CAC [14,17,44]. For example, tumor-bearing ATGL knockout
mice are protected from both adipose and muscle loss, ATGL has increased expression in
mouse models of CAC, and ATGL activity negatively correlates with body mass index in
CAC patients [7,17,35]. Although ATGL inhibitors have been developed for the treatment
of CAC [45,46], they have not yet been implemented in clinical trials [44]. Here, we
demonstrate that piceatannol acutely blunted lipolysis and lowered ATGL and CGI-58
protein levels with little effect on their mRNA levels in various cancer-associated conditions.
Importantly, piceatannol reduced glycerol release in TNF-α-stimulated lipolysis, despite
activation of HSL seen by Ser660 phosphorylation, suggesting the inability of other lipases
to compensate for ATGL loss. Together with others who have demonstrated an inability
of HSL to fully compensate for ATGL inhibition, our study adds further evidence of the
central role of ATGL in CAC lipolysis [47]. Taken together, these findings reveal a novel
function of piceatannol in regulating a central lipolytic pathway in models of CAC, in that
piceatannol targets lowering protein levels of the key lipolytic enzymes ATGL and CGI-58.
Increasing evidence demonstrates that adipose wasting occurs before muscle loss in
the early stage of CAC and preserving adipose mass early in CAC represents a promising
therapeutic strategy [7,13]. Slowing weight loss in CAC can improve quality of life and
increase survival outcomes in cancer patients, further emphasizing the need for weightstabilization strategies [4,10]. Consistent with other studies, we found that body weight loss
was driven primarily by adipose depletion in earlier stages of CAC [48]. Piceatannol-treated
mice, however, were completely protected from adipose loss in early CAC as judged by
an accurate analysis of body composition by EchoMRI. Despite preserving adipose in the
initial stages of CAC, piceatannol treatment did not significantly prolong survival; this
finding is consistent with others’ observation of lipolysis inhibition and adipose preservation without improved survival in similar models of CAC [25]. While adipose loss may be
a key feature of early cachexia, our results indicate that preventing WAT loss alone may
be insufficient to prolong survival. Although piceatannol has been previously reported to
suppress tumor progression in various cancer types such as mammary cancer [49], ovarian
cancer [50], and prostate cancer [51], we observed no effect of piceatannol on tumor size.
This discrepancy could be explained by a cancer-specific efficacy of piceatannol and/or
variation in piceatannol treatment regimens. Despite limited evidence from the current
study concerning a beneficial effect on survival or tumor size, piceatannol, due to its
adipose-preserving properties, could be used in combination with therapies that reduce tumor burden or preserve lean muscle mass. Indeed, strategies to preserve body weight early
in CAC are needed to complement other anti-cancer therapies [52,53]. Thus, investigations
of piceatannol’s complementary effect on anti-cancer therapies merit further research.
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Further investigation of the mechanism by which piceatannol preserves adipose tissue
is needed to better understand its therapeutic potential, as this study focused on “proof of
concept” of piceatannol’s anti-lipolytic role in in vitro models of CAC and adipose preservation in vivo. Notably, we recently demonstrated that piceatannol, unlike resveratrol,
plays an inhibitory role in both basal and stimulated lipolysis in cultured adipocytes, and
diet-induced obese mice [30]. We further found that piceatannol-inhibited lipolysis was
mediated by degradation of ATGL, CGI-58, and perilipin1 proteins through activation of
autophagy-lysosome pathway in adipocytes. Thus, future study should focus on investigating the molecular basis underlying piceatannol-regulated lipolytic protein clusters in
adipocytes under CAC conditions. Moreover, future studies could investigate the role of
piceatannol’s anti-inflammatory properties in addressing CAC, as inflammation plays a significant role in the progression of CAC [54]. Studies on piceatannol’s effect in other models
of CAC are also needed to more fully establish its protective properties. As causes of CAC
are complex and not completely understood, multiple approaches are needed to establish
causal relationships of therapeutic interventions. Furthermore, because piceatannol was administered interperitoneally in our study, studies using oral administration of piceatannol
would further inform optimal therapeutic strategies. Such studies would lay the groundwork to determine doses of piceatannol needed to achieve clinical significance, and whether
meaningful doses could be obtained with dietary or supplemental interventions.
5. Conclusions
In summary, we provide evidence of a protective role of piceatannol, a natural compound, in attenuating cancer-associated wasting. Using various in vitro models, we showed
that piceatannol treatment is sufficient to block pro-lipolytic CAC-associated stimuli. Furthermore, we confirmed that piceatannol induces ATGL degradation, an important target
to preserve body weight in CAC [17]. Although the causes of adipose loss in CAC are
complex, it is becoming increasingly apparent that downstream signaling effectors of
lipolysis, i.e., lipases, are of key importance [55]. Piceatannol’s anti-lipolytic properties
may translate to in vivo models, as piceatannol preserved adipose tissue in early stages
of cachexia. Synergistic effects of piceatannol with other anti-cancer therapies in CAC
paradigms merit further investigation.
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